Histogen Issued US Patent Covering CTS-2090 Methods

(24/7 MARKET NEWS) – Histogen Inc. (NASDAQ: HSTO) reported, after yesterday’s market close, that the US Patent and Trademark Office (USPTO) issued US Patent No. 11,579,703 titled “Caspase Inhibitors and Methods of Use Thereof”, which it expects to provide protection into 2040.

Histogen is trading at $1.07, up $0.2007 (+23.09%), on 1.8 million premarket shares traded.

Its 52-week trading range is $0.7603 to $9.40. It’s just below its next significant resistance point of $1.08. Its premarket high is $1.38 and its premarket low is $1.07.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist